ENDV.US Endonovo Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 14, 2026
Market cap
USD 181K
P/E
0.0x
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ENDV.US undervalued?

Graham number

The Graham number of Endonovo Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Endonovo Therapeutics Inc fundamental analysis

No fundamental analysis for Endonovo Therapeutics Inc yet.

Endonovo Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Endonovo Therapeutics Inc

Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver d…

Full company profile